- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05877963
Étude pour évaluer le maintien de l'efficacité lors de la transition d'un traitement anti-groupe de différenciation 20 (CD20) à l'ublituximab (ENHANCE)
Évaluation du maintien de l'efficacité lors de la transition d'un traitement anti-CD20 à l'ublituximab
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: TG Therapeutics Clinical Support Team
- Numéro de téléphone: 1-877-575-8489
- E-mail: clinicalsupport@tgtxinc.com
Lieux d'étude
-
-
-
Bydgoszcz, Pologne, 85-796
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Katowice, Pologne, 40-555
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Kielce, Pologne, 25-726
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Krakow, Pologne, 31-826
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Lodz, Pologne, 90-324
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Olsztyn, Pologne, 10-561
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Poznan, Pologne, 61-583
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Warsaw, Pologne, 04-141
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Zabrze, Pologne
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Żory, Pologne, 44-240
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35209
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Cullman, Alabama, États-Unis, 35058
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
California
-
Orange, California, États-Unis, 92697
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Colorado
-
Fort Collins, Colorado, États-Unis, 80528
- Recrutement
- TG Investigational Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20007
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Florida
-
Tampa, Florida, États-Unis, 33612
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30309
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Savannah, Georgia, États-Unis, 31406
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46256
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Kansas
-
Overland Park, Kansas, États-Unis, 66212
- Complété
- TG Therapeutics Investigational Trial Site
-
Overland Park, Kansas, États-Unis, 66205
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Maryland
-
Lutherville, Maryland, États-Unis, 21093
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 70809
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Boston, Massachusetts, États-Unis, 00002
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Foxborough, Massachusetts, États-Unis, 02035
- Recrutement
- TG Therapeutics Investigational Trial Site
-
North Worcester, Massachusetts, États-Unis, 01655
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Wellesley, Massachusetts, États-Unis, 02481
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Michigan
-
Farmington, Michigan, États-Unis, 48334
- Recrutement
- TG Investigational Site
-
-
Minnesota
-
Golden Valley, Minnesota, États-Unis, 55422
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Plymouth, Minnesota, États-Unis, 55446
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63131
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
New York
-
New York, New York, États-Unis, 10025
- Recrutement
- TG Therapeutics Investigational Trial Site
-
New York, New York, États-Unis, 11021
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28204
- Recrutement
- TG Therapeutics Investigational Trial SiteCharlotte
-
Raleigh, North Carolina, États-Unis, 27607
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45212
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Cleveland, Ohio, États-Unis, 44195
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Dayton, Ohio, États-Unis, 45417
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
South Carolina
-
Greenville, South Carolina, États-Unis, 29605
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Tennessee
-
Knoxville, Tennessee, États-Unis, 37922
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Complété
- TG Therapeutics Investigational Trial Site
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84103
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Virginia
-
Vienna, Virginia, États-Unis, 22182
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Washington
-
Kirkland, Washington, États-Unis, 98034
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Seattle, Washington, États-Unis, 98109
- Recrutement
- TG Therapeutics Investigational Trial Site
-
Spokane, Washington, États-Unis, 99208
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Recrutement
- TG Therapeutics Investigational Trial Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Diagnosis of RMS (2017 Revised McDonald criteria).
-
Participants must meet one of the following prior treatment definitions:
- Participants naïve to treatment.
- Participants previously treated with a disease modifying therapy (DMT) who have discontinued treatment prior to consent and meet the washout requirements.
-
Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.
-
Neurologically stable for > 30 days prior to first dose of ublituximab.
-
Female participants of childbearing potential must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 6 months after the last dose of ublituximab.
-
Part C: participants currently treated with an anti-CD20 agent for at least 6 months and meet the washout requirements prior to W1D1.
-
Part C: Discontinuation of current anti-CD20 must be due to suboptimal experience
Exclusion Criteria:
- History of any serious 3 Infusion Related Reaction (IRR) on prior anti-CD20 therapy.
- Primary-progressive multiple sclerosis (PPMS) or inactive Secondary Progressive MS (SPMS).
- Active chronic (or stable but treated with immune therapy) disease of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).
- Current evidence or known history of clinically significant infection, including: chronic, recurrent, or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment such as, but not limited to chronic urinary tract infection, chronic pulmonary infection with bronchiectasis, tuberculosis, or active hepatitis C virus (HCV).
- Previous serious opportunistic or atypical infection.
- Evidence of chronic active or history of hepatitis B virus (HBV) infection as evidenced by a detectable hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb), or chronic hepatitis C infection. Participants with positive hepatitis C virus antibody (HCV Ab) are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
- History or evidence (clinical, radiological, or biomarker) of suspected or confirmed progressive multifocal leukoencephalopathy (PML).
- Receipt of any live or live-attenuated vaccines (including vaccines for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration.
- Participants requiring treatment with intravenous immune globulin (IVIG) for decreased immunoglobulins within the 12 months prior to W1D1.
- Any active malignancies other than adequately treated basal, squamous cell or in situ carcinoma.
- Participants who have ever received ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab (including for non-MS indications).
Note: Other Inclusion/Exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part A: Ublituximab
Participants will receive a modified regimen of ublituximab including infusions on Day 1 of Week 1 (W1D1), Day 15, if applicable, and ublituximab 450 milligrams (mg) infusion at Week 24. With Protocol Version 6.0, enrollment in Part A was closed. |
Administered as an intravenous (IV) infusion.
Autres noms:
|
|
Expérimental: Part B: Ublituximab /Placebo (Treatment Arm A)
Participants will receive 600 mg of ublituximab on W1D1 followed by a placebo infusion on Day 15 and 450 mg ublituximab infusion at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
IV infusion Administered as an intravenous (IV) infusion.
Autres noms:
|
|
Expérimental: Part B: Ublituximab (Treatment Arm B)
Participants will receive 150 mg of ublituximab on W1D1 followed by 450 mg on Day 15 and at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
Administered as an intravenous (IV) infusion.
Autres noms:
|
|
Expérimental: Part C: Ublituximab (Treatment Arm C)
Participants will receive 150 mg of ublituximab on W1D1, followed by 450 mg on Day 15 and at Week 24. |
Administered as an intravenous (IV) infusion.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Partie B : Aire sous la courbe sur les 16 premières semaines (AUC0-S16) de l'ublituximab
Délai: Avant la dose et à plusieurs moments jusqu'à la semaine 16
|
Avant la dose et à plusieurs moments jusqu'à la semaine 16
|
|
|
Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48
Délai: Baseline up to Week 48
|
The Gd-enhancing T1 lesions will be evaluated using magnetic resonance imaging (MRI) technique. |
Baseline up to Week 48
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Parts A: Percentage of Participants Free of T1 Gd-Enhancing Lesions
Délai: Week 48
|
The Gd-enhancing T1 lesions will be evaluated using MRI technique. |
Week 48
|
|
Parts A and B: Percentage of Participants Experiencing Infusion Related Reactions (IRRs)
Délai: Up to Week 48
|
IRRs are defined as infusion related adverse events (AEs) that occur within one day of an infusion and resolve within 7 days. IRRs will be reported by investigator. |
Up to Week 48
|
|
Parts A: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores
Délai: Part A: Baseline, Week 24 and Week 48
|
The TSQM-9 is a 9-item questionnaire with 3 domains: Satisfaction, convenience, and effectiveness. |
Part A: Baseline, Week 24 and Week 48
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- TG1101-RMS401
- 2024-519284-18-00 (Autre identifiant: EU CT Number)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .